Cerus (CERS) Set to Announce Earnings on Wednesday

Cerus (NASDAQ:CERS) will post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Cerus to post earnings of ($0.03) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The business had revenue of $45.08 million during the quarter, compared to the consensus estimate of $42.50 million. During the same period in the previous year, the company posted ($0.07) EPS. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Up 2.5 %

CERS opened at $1.67 on Monday. The stock has a fifty day moving average of $1.93 and a 200-day moving average of $1.92. The company has a market capitalization of $308.77 million, a P/E ratio of -9.82 and a beta of 1.18. Cerus has a fifty-two week low of $1.25 and a fifty-two week high of $2.59. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.83 and a current ratio of 2.51.

Analyst Ratings Changes

Separately, Stifel Nicolaus decreased their target price on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $3.63.

Insider Buying and Selling

In other news, CFO Kevin Dennis Green sold 28,385 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the sale, the chief financial officer now owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the completion of the sale, the insider now directly owns 438,007 shares in the company, valued at $1,095,017.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Dennis Green sold 28,385 shares of Cerus stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the transaction, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.